

Referenser

Antikroppar mot "Glömskans sjukdom"?

1. Taheri-Targhi S, Gjedde A, Araj-Khodaei M, Rikhtegar R, Parsian Z, Zarrintan S, et al. Avicenna (980–1037 CE) and his Early Description and Classification of Dementia. *J Alzheimer's Dis* [Internet]. 2019 Oct 15 [cited 2025 June 19];71(4):1093–8. Available from: <https://journals.sagepub.com/action/showAbstract>
2. Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. *Alzheimer Dis Assoc Disord*. 2002;16(4):203–12.
3. Lautenschlager NT, Martins RN. Common versus uncommon causes of dementia. *Int Psychogeriatr*. 2005;17 Suppl 1:S27-34.
4. Alois Alzheimer. Über eine eigenartige Erkrankung der Hirnrinde. In Tübingen; 1906.
5. Alois Alzheimer. Über eigenartige Erkrankung der Hirnrinde. *Z Psychiatr* [Internet]. 1907 [cited 2025 June 23];64:146–8. Available from: <https://cir.nii.ac.jp/crid/1571135649977545216>
6. Emil Kraepelin. Klinische Psychiatrie. I. Teil, 8. Aufl. Psychiatrie. Lehrbuch für Studierende und Ärzte. 8th ed. Vol. 2. Leipzig: Barth; 1910.
7. Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. *J Neurol Sci* [Internet]. 1968 Sept 1 [cited 2025 June 19];7(2):331–56. Available from: <https://www.sciencedirect.com/science/article/pii/0022510X68901548>
8. Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. *J Neurol Sci* [Internet]. 1970 Sept 1 [cited 2025 June 19];11(3):205–42. Available from: <https://www.sciencedirect.com/science/article/pii/0022510X70900638>
9. Chiti F, Dobson CM. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. *Annu Rev Biochem* [Internet]. 2017 June 20 [cited 2025 June 19];86(Volume 86, 2017):27–68. Available from: <https://www.annualreviews.org/content/journals/10.1146/annurev-biochem-061516-045115>
10. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science*. 1988 Apr 29;240(4852):622–30.
11. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. *Ann Intern Med*. 2002 Aug 6;137(3):149–55.
12. Foley KE, Wilcock DM. Three major effects of APOEε4 on Aβ immunotherapy induced ARIA. *Front Aging Neurosci* [Internet]. 2024 May 2 [cited 2025 June 23];16. Available

from: <https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2024.1412006/full>

13. Bagyinszky E, Youn ,Young Chul, An ,Seong Soo A, and Kim S. The genetics of Alzheimer's disease. *Clin Interv Aging* [Internet]. 2014 Apr 1 [cited 2025 June 26];9:535–51. Available from: <https://www.tandfonline.com/doi/abs/10.2147/CIA.S51571>
14. Alzheimer's Disease Genetics Fact Sheet [Internet]. National Institute on Aging. 2023 [cited 2025 June 23]. Available from: <https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/alzheimers-disease-genetics-fact-sheet>
15. Genome.gov. 1972: First Recombinant DNA [Internet]. [cited 2025 June 19]. Available from: <https://www.genome.gov/25520302/online-education-kit-1972-first-recombinant-dna>
16. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* [Internet]. 1975 Aug [cited 2025 June 23];256(5517):495–7. Available from: <https://www.nature.com/articles/256495a0>
17. What are the updated recommendations for naming monoclonal antibodies? | Drug Information Group | University of Illinois Chicago [Internet]. [cited 2025 June 23]. Available from: <https://dig.pharmacy.uic.edu/faqs/2022-2/february-2022-faqs/what-are-the-updated-recommendations-for-naming-monoclonal-antibodies/>
18. Liu JKH. The history of monoclonal antibody development – Progress, remaining challenges and future innovations. *Ann Med Surg* [Internet]. 2014 Sept 11 [cited 2025 June 23];3(4):113–6. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284445/>
19. Durchschnittliche Lebenserwartung weltweit [Internet]. Laenderdaten.info. [cited 2025 June 25]. Available from: <https://www.laenderdaten.info/lebenserwartung.php>
20. World Fertility 2024 [Internet]. New York: United Nations.: United Nations; 2025 [cited 2025 June 25]. Report No.: UN DESA/POP/2024/TR/NO.11. Available from: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/un_desa_pd_2025_wfr_2024_final.pdf
21. World Population Ageing 2023 [Internet]. United Nations Department of Economic and Social Affairs, Population Division; 2023 [cited 2025 June 25] p. 14. Report No.: UN DESA/POP/2023/TR/NO.5. Available from: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/un_desa_pd_2024_wpa2023-report.pdf
22. Prince M, Knapp M, Guerchet M, McCrone P, Prina M, Comas-Herrera A, et al. Dementia UK: Update Second edition [Internet]. London: King's College London and the London School of Economics; 2014 Nov. Report No.: 978-1-906647-31–5. Available from: https://www.alzheimers.org.uk/sites/default/files/migrate/downloads/dementia_uk_update.pdf?fileID=2323

23. Center for Drug Evaluation and Research. FDA's Decision to Approve New Treatment for Alzheimer's Disease. FDA [Internet]. 2021 June 7 [cited 2025 June 23]; Available from: <https://www.fda.gov/drugs/our-perspective/fdas-decision-approve-new-treatment-alzheimers-disease>
24. Abushouk AI, Elmaraezy A, Aglan A, Salama R, Fouda S, Fouda R, et al. Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials. *BMC Neurol*. 2017 Apr 4;17(1):66.
25. Alzheimer's disease drug shelved after trial failure. BBC News [Internet]. 2012 Aug 7 [cited 2025 July 3]; Available from: <https://www.bbc.com/news/world-us-canada-19159167>
26. Carroll J. UPDATED: Pfizer, J&J Alzheimer's drug bapineuzumab flunks out in big PhIII | Fierce Biotech [Internet]. 2012 [cited 2025 July 3]. Available from: <https://www.fiercebiotech.com/r-d/updated-pfizer-j-j-alzheimer-s-drug-bapineuzumab-flunks-out-big-phiii>
27. Villegas S. Alzheimer's disease: New therapeutic strategies. *Med Clínica Engl Ed* [Internet]. 2015 July 20 [cited 2025 July 3];145(2):76–83. Available from: <https://www.sciencedirect.com/science/article/pii/S2387020615003605>
28. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. *Alzheimers Dement J Alzheimers Assoc*. 2012 July;8(4):261–71.
29. Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. *N Engl J Med*. 2018 Jan 25;378(4):321–30.
30. Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. Trial of Solanezumab in Preclinical Alzheimer's Disease. *N Engl J Med*. 2023 Sept 21;389(12):1096–107.
31. Lilly reaches end of the road with long-studied Alzheimer's drug | BioPharma Dive [Internet]. [cited 2025 July 3]. Available from: <https://www.biopharmadive.com/news/lilly-solanezumab-alzheimer-a4-amyloid-study-failure/644567/>
32. Biogen Netherlands. Withdrawal of Aduhelm (aducanumab) [Internet]. EMA; 2022 [cited 2025 June 23]. Available from: https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-aduhelm_en.pdf
33. Aduhelm | European Medicines Agency (EMA) [Internet]. 2022 [cited 2025 June 23]. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/aduhelm>
34. Biogen Walks Away From Aducanumab to Prioritize Lecanemab and Alzheimer Disease Pipeline [Internet]. *Neurology live*. 2024 [cited 2024 Nov 20]. Available from: <https://www.neurologylive.com/view/biogen-walks-away-from-aducanumab-prioritize-lecanemab-alzheimer-disease-pipeline>

35. [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer's disease [Internet]. [cited 2024 Nov 20]. Available from: <https://www.roche.com/media/releases/med-cor-2022-11-14>
36. Villain N, Planche V, Levy R. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. *Rev Neurol (Paris)*. 2022 Dec;178(10):1011–30.
37. FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease | Biogen [Internet]. [cited 2025 June 23]. Available from: <https://investors.biogen.com/news-releases/news-release-details/fda-accepts-leqembir-lecanemab-irmb-biologics-license>
38. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer's Disease. *N Engl J Med*. 2023 Jan 5;388(1):9–21.
39. Assessment report Leqembi [Internet]. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency; 2024 [cited 2025 June 23]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/leqembi-epar-public-assessment-report_en.pdf
40. Kisunla | European Medicines Agency (EMA) [Internet]. 2025 [cited 2025 Aug 15]. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/kisunla>
41. Wang H, Serap Monkul Nery E, Ardayfio P, Khanna R, Otero Svaldi D, Gueorguieva I, et al. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. *Alzheimers Dement* [Internet]. 2025 Apr 2 [cited 2025 Aug 15];21(4):e70062. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963282/>
42. Refusal of the marketing authorisation for Leqembi (lecanemab). Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency; 2024.
43. Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease | News Release: 2024 [Internet]. Eisai Co., Ltd. [cited 2025 June 24]. Available from: <https://www.eisai.com/news/2024/news202484.html>
44. Summary of opinion (initial authorisation) Leqembi lecanemab [Internet]. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency; 2025. Available from: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-leqembi_en.pdf
45. Leqembi | European Medicines Agency (EMA) [Internet]. 2024 [cited 2024 Nov 4]. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi>
46. Leqembi (lecanemab) [Internet]. [cited 2025 June 24]. Available from: <https://samverkanlakemedel.se/produktinfo/leqembi-lecanemab>
47. Wadström H, Stiller CO. Lekanemab (Leqembi) vid tidig Alzheimers sjukdom [Internet]. [cited 2025 June 24]. Available from: <https://samverkanlakemedel.se/download/18.25cdd0fd18e65a1a5d02da59/16989300747>

40/Lekanemab-vid-Alzheimers-sjukdom-tidig-bedomningsrapport-2023-05-31-justerad.pdf

48. Leqembi (lekanemab) vid Alzheimers sjukdom [Internet]. NT-rådet; 2025. Available from:
<https://samverkanlakemedel.se/download/18.4c651683196f6300a33bb9/1747997018030/Avvakta%20Leqembi%20vid%20Alzheimers%20sjukdom%202025-05-23.pdf>
49. Trysell K. NT-rådet: Avvakta med att använda lekanemab [Internet]. Läkartidningen. 2025 [cited 2025 June 24]. Available from:
<https://lakartidningen.se/aktuellt/nyheter/2025/05/nt-radet-avvakta-med-att-anvanda-lekanemab/>
50. Hälsoekonomiska bedömningar och rapporter klinikläkemedel - Tandvårds- och läkemedelsförmånsverket TLV [Internet]. 2025 [cited 2025 June 24]. Available from:
<https://www.tlv.se/lakemedelsforetag/halsoekonomiska-bedomningar-och-rapporter-kliniklakemedel.html>
51. Lecanemab (Leqembi) [Internet]. [cited 2025 Sept 10]. Available from:
<https://www.nyemetoder.no/metoder/lecanemab/>
52. Lecanemab: Breakthrough Alzheimer's Disease Medication Déjà vu | Michigan Medicine [Internet]. 2023 [cited 2025 Sept 10]. Available from:
<https://www.michiganmedicine.org/minding-memory/lecanemab-breakthrough-alzheimers-disease-medication-deja-vu>
53. Guilliot S, Gauthier S, Touchon J, Soto ME. Lithium, a Treatment Option for Alzheimer's Disease? A Review of Existing Evidence and Discussion on Future Perspectives. *J Alzheimers Dis JAD*. 2023;96(2):473–82.
54. Aron L, Ngian ZK, Qiu C, Choi J, Liang M, Drake DM, et al. Lithium deficiency and the onset of Alzheimer's disease. *Nature* [Internet]. 2025 Aug 6 [cited 2025 Aug 8];1–10. Available from: <https://www.nature.com/articles/s41586-025-09335-x>
55. Australian Public Assessment Report for Leqembi [Internet]. Australian Government, Department of Health and Aged Care, Therapeutic Goods Administration (TGA); 2025 [cited 2025 Sept 29]. Available from: <https://www.tga.gov.au/sites/default/files/2025-09/auspar-leqembi-250924.pdf>